Saruparib
Saruparib[edit | edit source]
Saruparib is a pharmaceutical drug that belongs to the class of PARP inhibitors. It is primarily used in the treatment of certain types of cancer, particularly those associated with BRCA mutations. Saruparib works by inhibiting the enzyme poly ADP ribose polymerase (PARP), which plays a crucial role in the repair of DNA damage in cells. By blocking this enzyme, Saruparib induces synthetic lethality in cancer cells that are already deficient in homologous recombination repair, leading to cell death.
Mechanism of Action[edit | edit source]
Saruparib targets the PARP enzyme, which is involved in the repair of single-strand breaks in DNA. In normal cells, PARP helps to repair these breaks, but in cancer cells with defective BRCA1 or BRCA2 genes, the repair process is compromised. Saruparib exploits this vulnerability by further inhibiting PARP, leading to the accumulation of DNA damage and ultimately causing cell death through apoptosis. This mechanism is particularly effective in tumors with BRCA mutations, as these cells rely heavily on PARP for DNA repair.
Clinical Use[edit | edit source]
Saruparib is used in the treatment of ovarian cancer, breast cancer, and other cancers associated with BRCA mutations. It is often prescribed for patients who have undergone previous treatments and have shown resistance to other forms of chemotherapy. The drug is administered orally and is part of a class of targeted therapies that aim to minimize damage to normal cells while effectively targeting cancer cells.
Side Effects[edit | edit source]
Common side effects of Saruparib include nausea, fatigue, anemia, and thrombocytopenia. Patients may also experience gastrointestinal disturbances such as diarrhea and vomiting. It is important for patients to be monitored regularly for hematological toxicity and other adverse effects during treatment.
Research and Development[edit | edit source]
Saruparib is the result of extensive research into PARP inhibitors and their potential in cancer therapy. Ongoing clinical trials are exploring its efficacy in combination with other anticancer agents and its potential use in a broader range of cancers. Researchers are also investigating biomarkers that could predict patient response to Saruparib, aiming to personalize treatment plans and improve outcomes.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD